Eli Lilly and Company
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Inclusion Criteria: * Participants must be 21 in Singapore. * Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change. Part A, B, D, and E * Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities: * hypertension * dyslipidemia * obstructive sleep apnea, or * prediabetes. Part C * Have a BMI ≥25.0 kg/m² * Have a diagnosis of Type 2 Diabetes (T2D) for at l…
administered SC
administered SC